Focus: Reliance Life Sciences is an India-based biotechnology company specializing in biosimilars, with a focused portfolio in oncology and hematology indications. The company operates as a mid-cap biotech with manufacturing and development capabilities centered in Navi Mumbai.
Profile data last refreshed 23m ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow Reliance Life Sciences to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Reliance Life Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Post-LOE generic chemotherapy agent generating legacy revenue but facing commodity price compression.
Help build intelligence for Reliance Life Sciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Post-LOE lung cancer therapeutic with folate antagonist mechanism; revenue erosion expected as generics proliferate.
Post-LOE proteasome inhibitor for blood cancers; limited differentiation in crowded biosimilar market.
Post-LOE epigenetic modulator for hematologic malignancies; niche indication with moderate revenue potential.
Post-LOE nucleic acid synthesis inhibitor for rare MDS subtypes; legacy revenue with long-term erosion risk.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub